Company intelligence / Profile preview

ELIXIR MD

Ownership: Private
Development stage: Commercial

Overview

ELIXIR MD™ offers an FDA-cleared medical-grade device designed exclusively for plastic surgeons to improve patient outcomes by shortening downtime, reducing complications such as bruising and swelling, and enhancing overall results. The technology is positioned as a transformative solution in operative care with a focus on both patient experience and provider efficiency. Clinical results are summarized as improved healing times and reduced common post-op issues based on user feedback; no formal clinical trial data is cited publicly.

Therapeutic areas: Other
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

5 assets

Detox

Commercial

Indications: Post-surgical recovery

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ELIXIR MD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELIXIR MD.

Explore the full profile